Advertisement

Topics

Human medicines European public assessment report (EPAR): Gefitinib Mylan, gefitinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 27/09/2018, Status: Authorised

01:58 EDT 13 Oct 2018 | European Medicines Agency

Human medicines European public assessment report (EPAR): Gefitinib Mylan, gefitinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 27/09/2018, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Gefitinib Mylan, gefitinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 27/09/2018, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Gefitinib Mylan, gefitinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 27/09/2018, Status: Authorised"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...